Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies
CW Freyer, DL Porter - Journal of Allergy and Clinical Immunology, 2020 - Elsevier
Chimeric antigen receptor T cells are a new and exciting immunotherapeutic approach to
managing cancer, with impressive efficacy but potentially life-threatening inflammatory
toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated
neurotoxicity syndrome (ICANS). Patients with severe CRS may develop capillary leak
syndrome and disseminated intravascular coagulation, with a cytokine signature similar to
that of macrophage activation syndrome/hemophagocytic lymphohistiocytosis. Moderate-to …
managing cancer, with impressive efficacy but potentially life-threatening inflammatory
toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated
neurotoxicity syndrome (ICANS). Patients with severe CRS may develop capillary leak
syndrome and disseminated intravascular coagulation, with a cytokine signature similar to
that of macrophage activation syndrome/hemophagocytic lymphohistiocytosis. Moderate-to …